Nymox Pharmaceutical Corporation Price Chart
Nymox Pharmaceutical Corporation NYM.SG Financial and Trading Overview
| Nymox Pharmaceutical Corporation stock price | 1.75 EUR |
| Previous Close | 1.75 EUR |
| Open | 1.72 EUR |
| Bid | 1.79 EUR x N/A |
| Ask | 1.83 EUR x N/A |
| Day's Range | 1.71 - 1.75 EUR |
| 52 Week Range | 1.07 - 2.78 EUR |
| Volume | 0 EUR |
| Avg. Volume | 38 EUR |
| Market Cap | 148.71M EUR |
| Beta (5Y Monthly) | 0.828873 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.174 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NYM.SG Valuation Measures
| Enterprise Value | 158.16M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -53.597 |
Trading Information
Nymox Pharmaceutical Corporation Stock Price History
| Beta (5Y Monthly) | 0.828873 |
| 52-Week Change | -6.91% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.78 EUR |
| 52 Week Low | 1.07 EUR |
| 50-Day Moving Average | 1.73 EUR |
| 200-Day Moving Average | 1.52 EUR |
NYM.SG Share Statistics
| Avg. Volume (3 month) | 38 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 83.73M |
| Float | 50.49M |
| Short Ratio | N/A |
| % Held by Insiders | 45.03% |
| % Held by Institutions | 1.11% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -204.28% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -2951000 EUR |
| Net Income Avi to Common (ttm) | -2877000 EUR |
| Diluted EPS (ttm) | -0.174 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 351K EUR |
| Total Cash Per Share (mrq) | 0.004 EUR |
| Total Debt (mrq) | 114K EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.194 |
| Book Value Per Share (mrq) | -0.02 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1986000 EUR |
| Levered Free Cash Flow (ttm) | -998041 EUR |
Profile of Nymox Pharmaceutical Corporation
| Country | Germany |
| State | N/A |
| City | Nassau |
| Address | Bay & Deveaux Streets |
| ZIP | N/A |
| Phone | 800 936 9669 |
| Website | https://nymox.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Q&A For Nymox Pharmaceutical Corporation Stock
What is a current NYM.SG stock price?
Nymox Pharmaceutical Corporation NYM.SG stock price today per share is 1.75 EUR.
How to purchase Nymox Pharmaceutical Corporation stock?
You can buy NYM.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nymox Pharmaceutical Corporation?
The stock symbol or ticker of Nymox Pharmaceutical Corporation is NYM.SG.
How many shares does Nymox Pharmaceutical Corporation have in circulation?
The max supply of Nymox Pharmaceutical Corporation shares is 84.98M.
What is Nymox Pharmaceutical Corporation Price to Earnings Ratio (PE Ratio)?
Nymox Pharmaceutical Corporation PE Ratio is now.
What was Nymox Pharmaceutical Corporation earnings per share over the trailing 12 months (TTM)?
Nymox Pharmaceutical Corporation EPS is -0.174 EUR over the trailing 12 months.